FIELD: organic chemistry, medicine, biochemistry, pharmacy.
SUBSTANCE: invention relates to the substituted pyrazoles, pharmaceutical compositions comprising these compounds and methods for their using in treatment of autoimmune diseases wherein cathepsin S is their mediating agent. Described substituted pyrazoles represent compounds of the formula (I): 
wherein a dotted line is placed near the group -C-R6 or absent, or it represents a bond; Y represents nitrogen atom or -CR20; Z represents nitrogen atom or -CR21; T represents nitrogen atom or -CR2; S represents nitrogen atom or -CR3 under condition that from 0 to 3 among S, T, Y and Z represent nitrogen atom, and additionally under condition that one among S, T, Y and Z can represent the group =N+-O- if other three are not nitrogen atom; R20 is chosen from hydrogen, halogen atom, hydroxy-, cyano-group, 4-7-membered heterocycle comprising nitrogen and oxygen atom; R21 represents hydrogen atom; R2 is chosen from hydrogen, halogen atom and hydroxy-group; R3 is chosen from hydrogen, halogen atom, (C1-C5)-alkoxy-group, (C1-C5)-alkyl, cyano-group, -RgRhN, 4-7-membered heterocyclyl comprising nitrogen and oxygen atom and -R17OC=O; R5 and R6 represent hydrogen atom; R7 and R8 can be combined in common and form optionally substituted 5-7-membered carbocylic or heterocyclic ring comprising nitrogen atom and wherein the indicated ring can be unsaturated or aromatic and this ring is substituted optionally with -Rt(C=O)- or -RtSO2; Rt represents (C1-C6)-alkyl; Rg, Rh and R17 represent (C1-C5)-alkyl; G represents (C3-C6)-alkanediyl; Ar represents monocyclic aryl ring optionally substituted from 1 to 3 substitutes chosen independently from halogen atom, (C1-C5)-alkyl and (C1-C5)-halogenalkyl; R32 represents hydrogen atom, (C1-C5)-alkyl, cyano-group, C1-C5)-hydroxyalkyl, -(C=O)NRvRx, -CHO or (C1-C6)-alkoxycarbonyl wherein each from Rv and Rx is chosen independently from hydrogen atom (H), (C1-C5)-alkyl, (C1-C5)-hydroxyalkyl, (C1-C5)-heterocyclyl comprising nitrogen and oxygen atom, (C1-C5)-heterocyclyl comprising nitrogen and oxygen atom-(C1-C5)-alkylene, (C1-C5)-aminoalkylene; Q represents -NR33, sulfur (S) or oxygen (O) atom; R33 represents hydrogen atom, (C1-C5)-alkyl, (C2-C5)-heterocyclyl comprising oxygen atom-(C1-C5)-alkylene, -R35OC=O and -R35OC=O; R35 represents (C1-C5)-alkyl, or their pharmaceutically acceptable salts, amides and esters, or their stereoisomeric forms.
EFFECT: improved for inhibition, valuable medicinal and biochemical properties of compounds and pharmaceutical composition.
25 cl, 3 tbl, 135 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF ALLERGY BY USING SUBSTITUTED PYRAZOLES | 2001 |
|
RU2259202C2 |
| SUBSTITUTED PYRAZOLES, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, USING PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF CATHEPSIN S ACTIVITY | 2001 |
|
RU2317988C2 |
| METHOD FOR TREATMENT OF ALLERGY BY USING SUBSTITUTED PYRAZOLES | 2001 |
|
RU2290179C2 |
| SUBSTITUTED PYRAZOLES | 2001 |
|
RU2286343C2 |
| METHOD FOR TREATMENT ALLERGY BY USING SUBSTITUTED PYRAZOLES | 2001 |
|
RU2277909C2 |
| PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP AS CRF ANTAGONISTS | 2005 |
|
RU2385321C2 |
| ANTAGONISTS OF CHEMOKINE RECEPTORS | 2013 |
|
RU2646762C2 |
| CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND USE THEREOF IN TREATING PSYCHOTIC DISORDERS | 2011 |
|
RU2586974C2 |
| COMPOUNDS TARGETING TAU PROTEIN AND RELATED USE THEREOF | 2017 |
|
RU2805523C2 |
| PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | 2011 |
|
RU2617405C2 |
